Biologic Therapeutic Delivery via Hydrophilic Polymer Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biologic therapeutics often require frequent and painful administration, leading to high systemic exposure and side effects, with no FDA-approved disease-modifying drugs for conditions like osteoarthritis, and existing treatments for macular degeneration involve repeated injections, decreasing efficacy and patient compliance.
Innovation Solution
Development of controlled, sustained release formulations using biologic therapeutics combined with hydrophilic polymer strands capable of inter-polymer cross-linking, forming a cross-linked composition that provides a triphasic release profile, reducing systemic exposure and increasing local concentration for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologic therapeutics are administered repeatedly to achieve therapeutic effect, then disease symptoms are controlled, but patient compliance decreases due to pain and frequency of administration
Solution Approach 1:
The biologic therapeutic is pre-loaded into biodegradable microspheres during manufacturing, creating a self-contained delivery system that releases the drug over time without requiring repeated patient visits for re-administration. This preliminary preparation transforms multiple injection events into a single administration event.
Solution Approach 2:
The microspheres are designed to provide continuous release of the biologic therapeutic over an extended period (weeks to months), maintaining therapeutic levels continuously rather than requiring periodic bolus doses. This continuous action eliminates the gaps between repeated administrations that cause compliance issues.
2Reliability
If high doses of biologic therapeutics are administered to ensure therapeutic effect, then disease symptoms are controlled, but systemic side effects increase
Solution Approach 1:
The microspheres are designed for localized administration at the disease site (e.g., intra-articular injection for osteoarthritis), creating a high local concentration of therapeutic where it is needed while minimizing systemic distribution. The controlled release from the local site ensures therapeutic efficacy without exposing the entire body to high drug levels.
Solution Approach 2:
The biodegradable polymer matrix of the microspheres acts as an intermediary carrier that controls the release kinetics of the biologic therapeutic. This intermediary system provides sustained local delivery, preventing the rapid systemic absorption that would lead to high peak concentrations and associated side effects.
3Reliability
If frequent administration of biologic therapeutics is performed to maintain therapeutic levels, then disease control is improved, but treatment cost increases
Solution Approach 1:
The microspheres are pre-loaded with sufficient biologic therapeutic to maintain effective levels throughout the intended treatment period. This preliminary dosing strategy eliminates the need for multiple follow-up administrations, reducing both the time patients must spend on treatment and the cumulative cost of repeated doses.
Solution Approach 2:
The extended-release microspheres maintain continuous therapeutic action over weeks or months, replacing the need for frequent periodic administrations. This continuous delivery reduces the total number of treatment events, thereby reducing time loss and associated treatment costs.
4Ease of operation
If controlled release formulations are used to reduce administration frequency, then patient compliance improves, but formulation complexity increases
Solution Approach 1:
The controlled release properties are achieved by adjusting parameters of the biodegradable polymer matrix (molecular weight, crystallinity, cross-linking density, composition ratios) rather than requiring complex mechanical or electronic release mechanisms. These parameter changes allow tuning of release kinetics while maintaining a relatively simple spherical microcapsule structure.
Solution Approach 2:
The microspheres utilize composite materials consisting of biodegradable polymers (such as PLGA, PLA, or PCL) combined with the biologic therapeutic. The composite structure provides both the mechanical integrity needed for stable delivery and the controlled degradation properties needed for sustained release, achieving complex functionality through material selection rather than structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve a significant reduction in systemic exposure, increase local concentration of biologic therapeutics, and improve patient compliance by providing a controlled release of biologic therapeutics for up to 90 days, maintaining therapeutic efficacy and minimizing side effects.
Implementation Method 1
each of said polymer strands comprises a functional group capable of inter-polymer polymerization
Implementation Method 2
the cross-linked composition exhibits reversible precipitation of the biologic therapeutic, wherein the precipitant includes precipitates of about 50 nm to about 10 μm in diameter
Implementation Method 3
controlled, sustained release formulations for biologic therapeutic delivery
Data Source
AI summary
Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm.